

Methodological Note 2024 for Pierre Fabre Limited

This note describes the methods used by Pierre-Fabre Limited (PFL) in the UK to meet its obligations and the requirements for disclosing payments and Transfers of Value (ToV) to Health Care Professionals (HCPs), Other Relevant Decision Makers (ORDMs) and Healthcare Organisations (HCOs) as outlined in The European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Code and further reflected in the Association of the British Pharmaceutical Industry (ABPI) Code of Practice.

The ToVs disclosed in this report cover payments made between 1st January and 31st December 2024, by PFL to HCPs, ORDMs and HCOs whose principal place of practice is the UK, in relation to activities and events. All ToVs have been disclosed on the date in which payment was made to the beneficiary, rather than the date the service was rendered, or an event took place.

Term	Methodology/Definition
Tax Consideration	It is the responsibility of the recipient of funding/ payment, for the settlement of any taxes due.
Value Added Tax (VAT)	Where possible direct payments are disclosed exclusive of VAT. ToVs for travel and accommodation (e.g., flight ticket, hotel room, etc.) are reported inclusive of VAT, where applicable. Payments in connection with research and development may include VAT.
Consent to Disclose	In 2024, PFL collected consent from HCPs to disclose payments on an individual named basis. If the HCP did not consent to disclose, the payment was reported in aggregate. Partial disclosure is included, if the HCP gives consent on some payments to disclose and other payments, they have not given consent, is reported in aggregate.
Currency	All ToVs are reported in Great British Pounds (GBP). If a payment was not made in GBP, the conversion rate applied was the rate that was provided by PFL's Corporate Disclosure platform on the date the disclosure report was extracted.
Cross Border Payments	For HCPs/ORDMs/HCOs whose principal place of practice is the UK and who received funding from an overseas PF affiliate, these ToVs are disclosed in the UK report.
Collaborative Working (HCO only)	No payments in relation to Collaborative Working projects have been made in 2024.

Methodological Note 2024 for Pierre Fabre Limited

<p>Contribution to Cost of Events: Sponsorship of agreements with HCOs</p>	<p>Events include scientific professional meetings, congresses, conferences, symposia, and other similar events.</p> <p>Where payment is made to third parties organising events on behalf of a single HCO, these are recorded as a ToV to the HCO beneficiary. If several HCOs or HCPs benefit, the ToV is reported against the third party (sometimes known as a Professional Conference Organiser (PCO)).</p>
<p>Contribution to Cost of Events: Registration fees (HCP)</p>	<p>Financial support to cover registration fees for Events including National or International Congresses.</p>
<p>Contribution to Cost of Events: Travel & Accommodation (HCP)</p>	<p>Travel (e.g., flight, train, taxi, mileage reimbursement, and parking). Hotel accommodation</p>
<p>Donations & Grants (D&G)</p>	<p>Donations include the provision of service, benefits-in-kind and physical items to support healthcare, scientific research or education paid to a healthcare, medical or scientific association upon receipt of an unsolicited request.</p> <p>Grants are the provision of funds to support healthcare, scientific research or education paid to a healthcare, medical or scientific association upon receipt of an unsolicited request.</p>
<p>Fees for Service and Consultancy (HCP)</p>	<p>ToVs resulting from or related to contracts between PFL and HCPs/ORDMs under which HCPs/ORDMs provide a service to PFL including: Speaker engagements Advisory Boards</p>
<p>Related expenses (HCP)</p>	<p>Travel and accommodation expenses incurred in relation to providing service/consultancy (e.g., flight, train, taxi, mileage reimbursement, parking, hotel accommodation).</p>
<p>Research and Development Transfers of Value</p>	<p>Transfers of Value to HCPs or HCOs related to the planning or conduct of:</p> <p>(i) non-clinical studies (as defined in OECD Principles on Good Laboratory Practice)</p> <p>(ii) clinical trials (as defined in Regulations 536/2014)</p>

Methodological Note 2024 for Pierre Fabre Limited

	(iii) non-interventional studies that are prospective in nature and that involve the collection of patient data from, or on behalf, of individual or groups of HCPs specifically for the study.
Multi-Year Contracts	Where contracts span multiple years, each individual ToV is captured and disclosed in the corresponding reporting period.